Evidence map›Paper›PMID 32511302›Full record

ArticlebioRxiv : the preprint server for biology2020

Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray.

Rafael R de Assis, Aarti Jain, Rie Nakajima, Algis Jasinskas, Jiin Felgner, Joshua M Obiero, Oluwasanmi Adenaiye, Sheldon Tai, Filbert Hong, Philip J Norris and 17 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 67 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 7 institutions in 2 countries.

Rafael R de AssisDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA.
Aarti JainDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA.
Rie NakajimaDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA.
Algis JasinskasDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA.
Jiin FelgnerDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA.
Joshua M ObieroDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA.
Oluwasanmi AdenaiyeInstitute for Applied Environmental Health, School of Public Health, University of Maryland, College Park, MD.
Sheldon TaiInstitute for Applied Environmental Health, School of Public Health, University of Maryland, College Park, MD.
Filbert HongDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA.
Philip J NorrisVitalant Research Institute, San Francisco, CA.
Mars StoneVitalant Research Institute, San Francisco, CA.
Graham SimmonsVitalant Research Institute, San Francisco, CA.
Anil BagriCerus Corporation, Concord, CA.
Martin SchreiberDepartment of Surgery, Oregon Health & Science University, Portland, OR.
Andreas BuserDivision of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Andreas HolbroDivision of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Manuel BattegayDivision of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Philip HosimerOrtho Clinical Diagnostics, Rochester, NY.
Charles NoesenOrtho Clinical Diagnostics, Rochester, NY.
Donald K MiltonInstitute for Applied Environmental Health, School of Public Health, University of Maryland, College Park, MD.
Prometheus Study Group
D Huw DaviesDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA.
Paul ContestableOrtho Clinical Diagnostics, Rochester, NY.
Laurence M CorashCerus Corporation, Concord, CA.
Michael P BuschVitalant Research Institute, San Francisco, CA.
Philip L FelgnerDepartment of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA.
Saahir KhanDivision of Infectious Diseases, Department of Medicine, University of California Irvine Health, Orange, CA.
University of California, Irvine · USUniversity of California, San Francisco · USUniversity of Basel · CHUniversity of Maryland, College Park · USCerus (United States) · USOrtho Clinical Diagnostics (United States) · USOregon Health & Science University · US

Funding

Institutional Career Development CoreKL2TR001416 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI CAIOZZO, VINCENT JAMES, DEMETRIOU, MICHAEL · 2015 to 2023
$5.6M
NCATS NIH HHS KL2 TR001416
6 · The paper itself

Abstract

The current practice for diagnosis of COVID-19, based on SARS-CoV-2 PCR testing of pharyngeal or respiratory specimens in a symptomatic patient at high epidemiologic risk, likely underestimates the true prevalence of infection. Serologic methods can more accurately estimate the disease burden by detecting infections missed by the limited testing performed to date. Here, we describe the validation of a coronavirus antigen microarray containing immunologically significant antigens from SARS-CoV-2, in addition to SARS-CoV, MERS-CoV, common human coronavirus strains, and other common respiratory viruses. A comparison of antibody profiles detected on the array from control sera collected prior to the SARS-CoV-2 pandemic versus convalescent blood specimens from virologically confirmed COVID-19 cases demonstrates near complete discrimination of these two groups, with improved performance from use of antigen combinations that include both spike protein and nucleoprotein. This array can be used as a diagnostic tool, as an epidemiologic tool to more accurately estimate the disease burden of COVID-19, and as a research tool to correlate antibody responses with clinical outcomes.

Identifiers

PMID32511302
PMCPMC7217240
OpenAlexW3016481695

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.